The US National Institutes of Health has made a deal with Pfizer, AstraZeneca, and Eli Lilly to share "abandoned experimental drugs" with academic researchers, reports ScienceInsider's Jocelyn Kaiser. The hope, Kaiser says, is that researchers will be able to find new uses for the drugs. The companies will grant access to two dozen compounds that have passed safety studies, but were deemed ineffective for a specific purpose.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.